Title Collaboration Type HHS Participating Agencies NIH Participating Institutes, Centers, and Offices Description
Microphysiological Systems for Drug Efficacy and Toxicity Testing Research Initiative FDA NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI, OD/DPCPSI/ORWH The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration, is leading this initiative to improve the process for predicting whether drugs will be safe in humans.
Microsystems Team Other FDA NIDDK, NINDS The NIH has identified a critical need for improved model systems to predict efficacy, safety, bioavailability, and toxicology outcomes for candidate therapeutics. This NIH FOA, supported by funds from the NIH Common Fund and participating NIH Institutes and Centers, invites applications for projects that will develop accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity. By definition, these cellular and organ microsystems will have a multicellular architecture representing the characteristics and functions of the tissue of origin and will demonstrate a reproducible and viable operation under physiological conditions over a long culture period. It is anticipated that these bio-engineered human tissue models could lead to the development and commercialization of microsystems that will enable rapid and high fidelity evaluation of safety and efficacy for candidate therapeutics.
Million Hearts Committee, Work group, Advisory group, or Task Force ACL, AHRQ, CDC, CMS, FDA, HRSA, SAMHSA NHLBI, NINDS The NIH provided input via CMS and CDC on the development and implementation of the Million Hearts Initiative.
Mobile apps for data collection on adverse events of medication or device during public health emergencies Resource Development FDA NLM NLM and FDA established a partnership to explore the development, assessment, and utilization of mobile applications to disseminate and exchange scientific information and data concerning reported adverse events from the use of a medication or medical device approved under the Emergency Use Authorization in a public health emergency or disaster.
Models of Infectious Disease Agent Study (MIDAS) (RFA) Research Initiative CDC NIGMS, FIC Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models will be useful to policymakers, public health workers and other researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid public officials in their decision-making processes.
Moving Towards a Coordinated HHS Approach to Sustainability: Strategies for Sustainable Change Committee, Work group, Advisory group, or Task Force CDC, HRSA, SAMHSA NHLBI The purpose of the collaborative activity was to plan a workshop with the HHS Office of Women''s Health entitled "Moving Towards a Coordinated HHS Approach to Sustainability: Strategies for Sustainable Change."
Mucosal Responses in the Context of Combination HIV-1 Prevention Meeting/ Workshop CDC NIAID This workshop will provide a unique opportunity for key investigators in the HIV vaccine and biomedical prevention fields to present current research data and approaches, and to discuss the best scientific path forward for developing combined HIV prevention modalities. The overall goal is to identify gaps to understand multicomponent prevention modalities that may be assessed in future clinical trials. Of particular interest are approaches designed to act synergistically and to identify modalities that may be potentially detrimental in regards to efficacy or safety.
Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group Research Initiative CMS, FDA OD/OSP, NHLBI, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIEHS, OD/DPCPSI This interagency working group, organized under the auspices of the Subcommittee on Biotechnology of the National Science and Technology Council (NTSC), coordinates federal funding, scientific meetings, regulatory guidance, standards development, funding efforts, and other key issues related to tissue engineering science. The working group enables Federal agencies involved in tissue engineering to stay informed of each other’s activities and coordinate efforts in a timely and efficient manner. In 2007, the working group published their federal-wide strategic plan for advancing tissue science and engineering. The working group is formally recognized by NIH/OD as a collaborative trans-NIH working group and is actively engaged with other agencies to accelerate progress in the tissue engineering field.
Multi-Payer Claims Database Resource Development AHRQ, OS NIA, OD/OSP The goals of the Multi-Payer Claims Database (MPCD) Pilot is to evaluate the value of a multi-payer claims database for comparative effectiveness research. The database will combine public and private claims data, providing investigators with access to data on a broad patient population.
Multinational Influenza Seasonal Mortality Study (MISMS) Research Research Initiative OS FIC, NHLBI, NIAID, NLM Multinational Influenza Seasonal Mortality Study (MISMS) was originally initiated to analyze national and global mortality patterns associated with influenza virus circulation. The focus of MISMS has since expanded to evaluate the interaction between the epidemiology, ecology, and evolutionary dynamics of influenza, including natural selection, reassortment, migration, and antigenic change. Multinational and bilateral collaborations developed by MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. Our research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 30 countries (representing ~3.2 billion people), resulting in over 100 publications.